Oncology ESMO25: On radiopharmaceutical possibilities in oncology, wi... At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.
Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
News Sanofi, Orano cue up filings for GEP-NET radioligand therapy Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
Oncology Advancing radiopharmaceutical development: Preclinical preci... Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.
News Radiopharma CDMO Nucleus names former FDA boss as CEO CDMO Nucleus RadioPharma has a high-profile new CEO: former FDA Commissioner and veteran cancer researcher Dr Stephen Hahn.
News New radiopharma Actithera emerges with $75.5m in financing A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.